Fundraising FoxHarrow Health
NASDAQ: HROWNashville, US · Delaware corporation
Find your way into Harrow Health
Sign up to see every warm intro you have to Harrow Health
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Harrow Health team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Harrow Health develops and sells branded ophthalmic medications and medical devices for conditions including dry eye disease, age-related macular degeneration, glaucoma, and cataracts through direct sales to U.S. eyecare professionals, and operates a pharmaceutical compounding pharmacy serving ophthalmologists with customized formulations.
Founders & leadership
ML
Mark L. BaumChairman of the Board and Chief Executive OfficerMark L. Baum is Chairman and Chief Executive Officer of Harrow Health, which develops and markets branded ophthalmic medications and devices for conditions such as dry eye disease and age-related macular degeneration, and operates a pharmaceutical compounding pharmacy for ophthalmologists. He has spent over 25 years building and investing in businesses across various sectors.
AR
Andrew R BollExecutiveAndrew Boll is an executive officer at Harrow Health, a developer of ophthalmic medications and medical devices, where he oversees financial operations, M&A, and corporate development. He has been involved in founding or leading multiple pharmaceutical and ophthalmic companies including Eton Pharmaceuticals, Surface Ophthalmics, Melt Pharmaceuticals, and ImprimisRx, and previously held an accounting leadership role at an investment company.
Board
RL
Richard L LindstromBoard director
RJ
Robert J KammerBoard director
TF
Teresa F SparksBoard director
RL
R Larry Van HornBoard director
Reported raises · per SEC filings
Form D private placements$21.3M disclosed across 4 rounds · 2011–2021
▶$10.7MraisedMay 2021 · 1 investors · PharmaceuticalsRule 506(b)
▶$10.7MraisedMay 2021 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Andrew R BollExecutive Officer
- Richard L LindstromDirector
- Robert J KammerDirector
- Mark L BaumExecutive Officer
- Teresa F SparksDirector
- R Larry Van HornDirector
- Offering amount
- $10.7M
- Amount sold
- $10.7M
- First sale
- May 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$10.1MraisedDec 2016 · 143 investors · PharmaceuticalsRule 506(b)
▶$10.1MraisedDec 2016 · 143 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Robert KammerDirector
- Anthony PrincipiDirector
- Andrew BollExecutive Officer
- Richard LindstromDirector
- Stephen AustinDirector
- Mark BaumExecutive Officer, Director
- Offering amount
- $10.1M
- Amount sold
- $10.1M
- Sales commissions
- $755.2K
- Placement agents
- National Securities Corporation
- First sale
- Dec 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$500KraisedJan 2015 · 2 investors · PharmaceuticalsRule 506(b)
▶$500KraisedJan 2015 · 2 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Richard L. LindstromDirector
- Robert J. KammerDirector
- Andrew R. BollExecutive Officer
- Mark L. BaumExecutive Officer, Director
- Stephen G. AustinDirector
- William H. NelsonDirector
- Offering amount
- $818.8K
- Amount sold
- $500K
- First sale
- Jan 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed events$35.6Mvaluation at IPOFeb 2013 · $5.25/share · 424B4
filing ↗Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Frequently asked questions
- What does Harrow Health do?
- Harrow Health develops and sells branded ophthalmic medications and medical devices for conditions including dry eye disease, age-related macular degeneration, glaucoma, and cataracts through direct sales to U.S. eyecare professionals, and operates a pharmaceutical compounding pharmacy serving ophthalmologists with customized formulations.
- Who founded Harrow Health?
- Harrow Health was founded by Mark L. Baum.
- How much funding has Harrow Health raised?
- Harrow Health has disclosed $21.3M raised across 4 rounds.
- Where is Harrow Health headquartered?
- Harrow Health is headquartered in Nashville, US.